Bright Minds Biosciences Inc. (DRUG)
| Market Cap | 878.77M +192.1% |
| Revenue (ttm) | n/a |
| Net Income | -19.60M |
| EPS | -2.48 |
| Shares Out | 9.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,613 |
| Open | 88.73 |
| Previous Close | 89.49 |
| Day's Range | 87.40 - 90.67 |
| 52-Week Range | 23.18 - 123.75 |
| Beta | -0.19 |
| Analysts | Strong Buy |
| Price Target | 169.22 (+92.14%) |
| Earnings Date | Jun 9, 2026 |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neurop... [Read more]
Analyst Summary
According to 7 analysts, the average rating for DRUG stock is "Strong Buy." The 12-month stock price target is $169.22, which is an increase of 92.14% from the latest price.
News
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ago...
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Bright Minds price target raised to $220 from $190 at Piper Sandler
Piper Sandler raised the firm’s price target on Bright Minds (DRUG) to $220 from $190 and keeps an Overweight rating on the shares. The firm caught up with Bright Minds…
Bright Minds Biosciences Registration statement: Q2 2026
Bright Minds Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Registration statement: Q2 2026
Bright Minds Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
DRUG Initiates Coverage On Bright Minds Biosciences -- Price Target Announced
DRUG Initiates Coverage On Bright Minds Biosciences -- Price Target Announced
Bright Minds initiated with a Buy at Jefferies
Jefferies initiated coverage of Bright Minds (DRUG) with a Buy rating and $145 price target The firm says the company’s oral BMB-101 is a potential best-in-class 5-HT2C agonist. BMB-101 has
Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript
Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript
Bright Minds Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
BMB-101 demonstrated strong efficacy and safety in refractory seizure disorders, with phase III trials in epilepsy and Prader-Willi syndrome underway. Both indications are seen as multi-billion dollar opportunities, and recent financing supports multiple upcoming clinical readouts.
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Bright Minds (DRUG) to $145 from $115 and keeps a Buy rating on the shares. The firm says the BREAKTHROUGH Phase 2
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag...
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
Bright Minds price target lowered to $126 from $142 at Baird
Baird lowered the firm’s price target on Bright Minds (DRUG) to $126 from $142 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results
Bright Minds Biosciences Registration statement: Q1 2026
Bright Minds Biosciences filed a registration statement on February 11, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Registration statement: Q1 2026
Bright Minds Biosciences filed a registration statement on February 11, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 ...
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering...
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Full story available on Benzinga.com
Bright Minds price target raised to $142 from $82 at Baird
Baird raised the firm’s price target on Bright Minds (DRUG) to $142 from $82 and keeps an Outperform rating on the shares. The firm updated its model following the release
Bright Minds price target raised to $147 from $72 at BTIG
BTIG raised the firm’s price target on Bright Minds (DRUG) to $147 from $72 and keeps a Buy rating on the shares. The first readout for BMB-101 in absence seizures
Bright Minds announces $100M common shares offering
Bright Minds (DRUG) Biosciences announced the launch of a public offering of common shares in the capital of the company and, in lieu of common shares to investors that so
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the...
BTIG Raises Price Target for Bright Minds Biosciences (DRUG) to $147 | DRUG Stock News
BTIG Raises Price Target for Bright Minds Biosciences (DRUG) to $147 | DRUG Stock News
Bright Minds Biosciences Inc BMB-101 Topline data announcement Transcript
Bright Minds Biosciences Inc BMB-101 Topline data announcement Transcript